SCHEMBL1122123

SCHEMBL1122123

O=S(=O)(CC1(F)CN(C(c2ccccc2)c2ccccc2)C1)c1ccc(F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 7/20 0.43
USP2 O75604 6/20 0.43
CYP2D6 P10635 5/20 0.43
CYP2C9 P11712 4/20 0.43
OPRD1 P41143 3/20 0.42
OPRM1 P35372 2/20 0.42
OPRK1 P41145 2/20 0.42
OPRL1 P41146 2/20 0.42
KMT2A Q03164 2/20 0.41
CACNA2D1 P54289 1/20 0.41
CACNA1B Q00975 1/20 0.41
CACNB1 Q02641 1/20 0.41
CACNA1C Q13936 1/20 0.41
MEN1 O00255 1/20 0.41
ATM Q13315 1/20 0.41
ALOX15 P16050 1/20 0.41
PKM P14618 1/20 0.39
CYP1A2 P05177 1/20 0.38
ALDH1A1 P00352 2/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6506915 0.78 LMNA (0.33) USP2PKMMAPT
Hydrochloric Acid SCHEMBL5189110 0.77 LMNA (0.32) USP2
SCHEMBL1121906 0.76 KMT2A (0.43) OPRD1OPRM1OPRK1OPRL1KMT2A
SCHEMBL13182972 0.70 CYP2D6 (0.47) CYP3A4USP2CYP2D6CYP2C9OPRD1
SCHEMBL1741852 0.69 OPRM1 (0.54) CYP3A4USP2CYP2D6CYP2C9OPRD1
SCHEMBL5827168 0.68 ALDH1A1 (0.48) CYP3A4USP2CYP2D6KMT2AMEN1
SCHEMBL2656183 0.68 CYP2D6 (0.55) CYP3A4USP2CYP2D6CYP2C9OPRD1
SCHEMBL6011753 0.68 OPRM1 (0.47) CYP3A4USP2CYP2D6CYP2C9OPRD1
Hydrochloric Acid SCHEMBL1121811 0.68 ALDH1A1 (0.47) CYP3A4USP2CYP2D6KMT2AMEN1
SCHEMBL18035049 0.67 NPSR1 (0.45) CYP3A4USP2CYP2D6CYP2C9OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1685100-B1 NOVEL 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS MERCK SHARP & DOHME (GB) 2011-02-09 EP disclosed
US-7094777-B2 5-HT2A receptor ligands MERK SHARP & DOHME LTD. 2006-08-22 US disclosed
WO-2005047247-A1 NOVEL1,3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS MERCK SHARP & DOHME LIMITED (GB) 2005-05-26 WO disclosed
US-20050101586-A1 Novel 5-HT2A receptor ligands MERCK SHARP & DOHME LTD. (GB) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101586-A1 Novel 5-HT2A receptor ligands HTR2A, HTR1A, HTR5A CYP3A4 1345/4885USP2 2574/4885CYP2D6 532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.